NCT01386580View on ClinicalTrials.gov

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Brain MetastasesLung CancerBreast CancerMelanomaMalignant Glioma
Interventions
DRUG

2B3-101

IV every 21 days

DRUG

Trastuzumab

IV every 21 days

DRUG

2B3-101 60 mg/m2 every 4 weeks

IV every 28 days

DRUG

2B3-101 50 mg/m2 every 3 weeks

IV every 21 days

Trial Locations (10)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

75248

Institut Curie, Paris

94805

Institut Gustave Roussy, Villejuif

B-2650

Universitair Ziekenhuis Antwerpen, Antwerp

B-1000

Jules Bordet Institute, Brussels

1066 CX

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

1081 HV

Vrije Universiteit medisch centrum (Vumc), Amsterdam

2333 CA

Leids Universitair Medisch Centrum (LUMC), Leiden

6229 HX

Maastricht Universitair Medisch Centrum, Maastricht

3075 EA

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

BBB-Therapeutics B.V.

INDUSTRY

NCT01386580 - An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | Biotech Hunter | Biotech Hunter